Market Overview

Neuralstem Issues License for Central Nervous System Therapy Surgical Devices to Cedars-Sinai

Related CUR
Actinium Set To Follow In Opko's Foosteps Amid Near Term Catalysts
Neuralstem Reports First Patient Treated In China Stem Cell Trial to Treat Stroke Motor Deficits

Neuralstem, Inc. (NYSE: CUR) announced that it has granted licenses to intellectual property surrounding its spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents to the spinal cord to Cedars-Sinai Medical Center, a non-profit academic medical center located in Los Angeles, CA. The license agreements grant Cedars-Sinai Medical Center the non-exclusive right to use the licensed intellectual property in academic research. This is the second group of licenses announced by Neuralstem for these technologies. The financial terms of the agreement were not disclosed. Neuralstem holds the exclusive worldwide licenses to the platform and cannula technologies. 

The platform and cannula have been used since 2010 in a Phase I ALS trial, sponsored by Neuralstem and recently completed at Emory University, covering the delivery of Neuralstem's NSI-566 neural stem cells into the spinal cords of patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Neuralstem recently received FDA approval to commence a Phase I trial in chronic spinal cord injury using the platform and cannula technologies.

Posted-In: News

 

Related Articles (CUR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters